PHILIP LUPO to Rhabdomyosarcoma
This is a "connection" page, showing publications PHILIP LUPO has written about Rhabdomyosarcoma.
Connection Strength
7.561
-
The impact of genetic ancestry on survival outcomes in pediatric rhabdomyosarcoma: A report from the Children's Oncology Group. HGG Adv. 2025 Jul 10; 6(3):100466.
Score: 0.768
-
Improving Individualized Rhabdomyosarcoma Prognosis Predictions Using Somatic Molecular Biomarkers. JCO Precis Oncol. 2025 Feb; 9:e2400556.
Score: 0.751
-
Germline Genetic Testing and Survival Outcomes Among Children With Rhabdomyosarcoma: A Report From the Children's Oncology Group. JAMA Netw Open. 2024 03 04; 7(3):e244170.
Score: 0.704
-
Children's Oncology Group's 2023 blueprint for research: Epidemiology. Pediatr Blood Cancer. 2023 09; 70 Suppl 6:e30566.
Score: 0.673
-
Germline genetic variants and pediatric rhabdomyosarcoma outcomes: a report from the Children's Oncology Group. J Natl Cancer Inst. 2023 06 08; 115(6):733-741.
Score: 0.669
-
Pediatric rhabdomyosarcoma incidence and survival in the United States: An assessment of 5656 cases, 2001-2017. Cancer Med. 2023 02; 12(3):3644-3656.
Score: 0.635
-
Germline Cancer Predisposition Variants in Pediatric Rhabdomyosarcoma: A Report From the Children's Oncology Group. J Natl Cancer Inst. 2021 07 01; 113(7):875-883.
Score: 0.585
-
The Role of Childhood Infections and Immunizations on Childhood Rhabdomyosarcoma: A Report From the Children's Oncology Group. Pediatr Blood Cancer. 2016 09; 63(9):1557-62.
Score: 0.410
-
Maternal and birth characteristics and childhood rhabdomyosarcoma: a report from the Children's Oncology Group. Cancer Causes Control. 2014 Jul; 25(7):905-13.
Score: 0.357
-
Allergies, atopy, immune-related factors and childhood rhabdomyosarcoma: a report from the Children's Oncology Group. Int J Cancer. 2014 Jan 15; 134(2):431-6.
Score: 0.338
-
Salvage Therapy Efficacy is Modified by Risk Group at Diagnosis in Patients With Relapsed Rhabdomyosarcoma. Pediatr Blood Cancer. 2025 Mar; 72(3):e31477.
Score: 0.186
-
A systematic review of the prevalence of pathogenic or likely pathogenic germline variants in individuals with FOXO1 fusion-positive rhabdomyosarcoma. Pediatr Blood Cancer. 2023 11; 70(11):e30651.
Score: 0.170
-
Impact of race and ethnicity on presentation and outcomes of patients treated on rhabdomyosarcoma clinical trials: A report from the Children's Oncology Group. Cancer Med. 2023 06; 12(11):12777-12791.
Score: 0.166
-
Alveolar rhabdomyosarcoma has superior response rates to vinorelbine compared to embryonal rhabdomyosarcoma in patients with relapsed/refractory disease: A meta-analysis. Cancer Med. 2023 05; 12(9):10222-10229.
Score: 0.165
-
Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: A consensus view from European paediatric Soft tissue sarcoma Study Group, Children's Oncology Group and Cooperative Weichteilsarkom-Studiengruppe. Eur J Cancer. 2022 09; 172:367-386.
Score: 0.157
-
Is Detection of Relapse by Surveillance Imaging Associated With Longer Survival in Patients With Rhabdomyosarcoma? J Pediatr Hematol Oncol. 2022 08 01; 44(6):305-312.
Score: 0.153
-
Pathogenic Germline Variants in Cancer Susceptibility Genes in Children and Young Adults With Rhabdomyosarcoma. JCO Precis Oncol. 2021; 5.
Score: 0.142
-
Insights into pediatric rhabdomyosarcoma research: Challenges and goals. Pediatr Blood Cancer. 2019 10; 66(10):e27869.
Score: 0.127
-
Rhabdomyosarcoma. Nat Rev Dis Primers. 2019 01 07; 5(1):1.
Score: 0.123
-
Does Routine Imaging of Patients for Progression or Relapse Improve Survival in Rhabdomyosarcoma? Pediatr Blood Cancer. 2016 Feb; 63(2):202-5.
Score: 0.098
-
Family history of cancer and childhood rhabdomyosarcoma: a report from the Children's Oncology Group and the Utah Population Database. Cancer Med. 2015 May; 4(5):781-90.
Score: 0.095
-
Parental military service, agent orange exposure, and the risk of rhabdomyosarcoma in offspring. J Pediatr. 2014 Dec; 165(6):1216-21.
Score: 0.091